超短效β_1-肾上腺素受体阻断剂——盐酸兰地洛尔的研发和临床应用  

The Design and Clinical Application of Landiolol Hydrochloride,an Ultra Short-acting β_1-Blocker

作　　者：张倩[1] 冯明声 曹于平 姚其正[1] 

机构地区：[1]中国药科大学药学院,江苏南京210009 [2]南京海辰药业有限公司,江苏南京210046

出　　处：《中国医药指南》2012年第9期7-9,共3页Guide of China Medicine

摘　　要：盐酸兰地洛尔是超短效β1-肾上腺素受体阻断剂,由日本小野制药工业株式会社(Ono)最早开发,用于手术时心动过速性心律失常的紧急治疗;后适应证追加手术后循环动态监视下对心动过速性心律失常的紧急治疗,获得批准。本文综述了盐酸兰地洛尔的设计研发、特性及其在临床研究中的新进展。Landiolol hydrochloride is a novel,highly cardioselective ultra short-acting beta-blocker,has been developed by Ono Pharmaceutical Co.,Ltd.for application in the emergency treatment of tachycardia and better control of heart rate in surgery in 2002.Landiolol hydrochloride was approved for emergency treatment of tachycardia arrhythmia after surgery in 2006.The design,developing and characteristics of landiolol hydrochloride,and its recent advances of the clinical research were reviewed in this article.

关 键 词：超短效β1-受体阻断剂 盐酸兰地洛尔 软药设计 临床应用 

分 类 号：R969[医药卫生—药理学]